"I want to tell you about a new cancer fighting biotech name that's probably not on your radar screen," said Cramer. "The company is Celldex Therapeutics, a $13 stock with a $1 billion market cap."
Although the stock is already up 90% since the beginning of the year, Cramer thinks the stock has more room to run.
"Celldex is doing ground breaking work in one of the hottest parts of the oncology universe, what's known as cancer immunotherapy," Cramer explained. "These are drugs that use the body's natural defenses, the immune system, to target and destroy cancer cells."
This form of therapy is expected to be a big theme going forward in cancer treatment.
Currently conventional treatments such as chemotherapy are broad based – that is, they destroy both cancerous tissue as well as healthy tissue and come with very serious side effects.
Celldex's technology however is different – it's targeted.
"It's engineered to make the cells in your immune system go on a search and destroy mission, looking for specific tumors. And from the data we've seen so far, the company's approach works really well without causing harmful side effects," Cramer said.